Journal of Medical Economics

Papers
(The H4-Index of Journal of Medical Economics is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs92
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study62
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi50
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in 48
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis37
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study34
The economic burden of systemic lupus erythematosus in Taiwan29
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing27
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review27
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States27
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych26
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm24
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective24
Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries24
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment24
Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries22
Utilities associated with stoma-related complications: peristomal skin complications and leakages21
Challenges in health economics research: insights from real-world examples20
Economic review of point-of-care EEG19
0.25074195861816